title: Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors.
abstract: BACKGROUND
  Ewing's sarcoma family of tumors (ESFT) is one of the most malignant groups of tumors in young people. Human leukocyte antigen (HLA) class I displays endogenously processed peptides to CD8+ T lymphocytes and has a key role for host immune surveillance. In ESFT, the investigation concerning both HLA class I expression and T-cell infiltration has yet to be reported.
  
  
  METHODS
  Biopsy specimens from 28 ESFT patients were evaluated by immunohistochemistry with the anti-HLA class I monoclonal antibody (mAb) EMR8-5 and anti-CD8 mAb, respectively.
  
  
  RESULTS
  Expression of HLA class I was negative in 10 tumors and down-regulated in 22 tumors. The status of CD8+ T cell infiltration was closely associated with the expression levels of HLA class I. ESFT patients with down-regulated or negative expression of HLA class I showed significantly poorer survival than the rest of the patients.
  
  
  CONCLUSIONS
  Our results suggested that CD8+ T cell-mediated immune response restricted by HLA class I might play an important role in immune surveillance of ESFT, and we revealed for the first time that the status of HLA class I expression affects the survival of the patients with ESFT.
authors.affiliation: Division of Rheumatology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yabe
authors.forename: Tomohide
authors.initials: T
authors.lastname: Tsukahara
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kawaguchi
authors.forename: Takuro
authors.initials: T
authors.lastname: Wada
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Torigoe
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Sato
authors.forename: Chihiro
authors.initials: C
authors.lastname: Terai
authors.forename: Masaya
authors.initials: M
authors.lastname: Aoki
authors.forename: Shigemichi
authors.initials: S
authors.lastname: Hirose
authors.forename: Hideo
authors.initials: H
authors.lastname: Morioka
authors.forename: Hiroo
authors.initials: H
authors.lastname: Yabe
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D015395:Histocompatibility Antigens Class I / Q000378:metabolism*; D006801:Humans; D007223:Infant; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012512:Sarcoma, Ewing / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D015996:Survival Rate; D055815:Young Adult
chemical_list: D015395:Histocompatibility Antigens Class I